ABBVIE SP. Z O.O. secures contract for Pharmaceutical products - Delivery of the medicinal product Mirvetuximab soravtansine as part of the B50 Drug Program TREATMENT OF PATIENTS WITH OVARIAN CANCER, Fallopian tube cancer or peritoneal cancer - 1 product package

Poland, Jan. 2 -- Poland based ABBVIE SP. Z O.O. has secured contract from UNIWERSYTECKI SZPITAL KLINICZNY W POZNANIU for Pharmaceutical products - Delivery of the medicinal product Mirvetuximab soravtansine as part of the B50 Drug Program TREATMENT OF PATIENTS WITH OVARIAN CANCER, Fallopian tube cancer or peritoneal cancer - 1 product package. The value of the contract is worth 1007999424 PLN.

Published by HT Digital Content Services with permission from Pivotal Sources....